Study guide
6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
BCOP Board Certified Oncology Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & BCOP Exam Foundations
1.1 BCOP Exam Specifications, Passing Standard & Eligibility 1.2 The Clinical Oncology Pharmacist Scope of Practice & Core Competencies 1.3 Study Guide Methodology & Active Learning Strategy
2 Chapter 2: Cancer Biology & Pathophysiology
2.1 Hallmarks of Cancer, Multi-Step Carcinogenesis & Tumor Microenvironment 2.2 Cell Cycle Checkpoints, Apoptotic Pathways & DNA Damage Repair Mechanics 2.3 Tumor Immunology, Antigen Presentation & Mechanisms of Immune Evasion
3 Chapter 3: Genomic Biomarkers & Molecular Targets
3.1 Somatic vs Germline Mutations, NGS Profiling & Variant Classification 3.2 Actionable Oncogenic Driver Mutations & Targeted Kinase Inhibitors 3.3 Pharmacogenomics in Oncology: DPYD, TPMT, NUDT15, UGT1A1 & CYP2D6
4 Chapter 4: Diagnostics, Staging & Clinical Assessment
4.1 Circulating Tumor Markers, Flow Cytometry & Diagnostic Modalities 4.2 TNM Staging Systems, Histopathologic Grading & Hematologic Prognostic Indices 4.3 Performance Status Scales & Organ Function Assessment 4.4 Cancer Screening, Early Detection & Prevention
5 Chapter 5: Cytotoxic Chemotherapy Pharmacology & Regimens
5.1 Alkylating Agents & Platinum Analogs 5.2 Antimetabolites & Folate Antagonists 5.3 Topoisomerase Inhibitors, Anthracyclines & Cardiotoxicity Mitigation 5.4 Antimicrotubule Agents: Taxanes, Vinca Alkaloids & Halichondrins
6 Chapter 6: Targeted Small-Molecule Therapies
6.1 Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumors 6.2 Hematologic Small-Molecule Kinase Inhibitors 6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
7 Chapter 7: Immunotherapy, Biologics & Cellular Therapy
7.1 Immune Checkpoint Inhibitors & irAE Management 7.2 Naked Monoclonal Antibodies, Antibody-Drug Conjugates & Bispecific T-Cell Engagers 7.3 Chimeric Antigen Receptor (CAR) T-Cell Therapies & Cellular Logistics
8 Chapter 8: Breast & Gynecologic Malignancies
8.1 Early-Stage & Locoregional Breast Cancer 8.2 Advanced & Metastatic Breast Cancer Targeted Strategies 8.3 Epithelial Ovarian, Endometrial & Cervical Malignancies
9 Chapter 9: Thoracic & Skin Malignancies
9.1 Early & Locally Advanced NSCLC & Small Cell Lung Cancer 9.2 Metastatic Non-Small Cell Lung Cancer (Driver-Positive and Driver-Negative) 9.3 Cutaneous Melanoma & Non-Melanoma Skin Cancers
10 Chapter 10: Gastrointestinal & Genitourinary Malignancies
10.1 Colorectal Cancer: Staging, Adjuvant Therapy, and Biomarker-Driven Metastatic Therapeutics 10.2 Esophagogastric, Pancreatic, and Hepatobiliary Malignancies 10.3 Genitourinary Malignancies: Prostate, Renal Cell, and Urothelial Carcinomas
11 Chapter 11: Hematologic Malignancies: Leukemias & Myeloma
11.1 Acute Myeloid & Acute Lymphoblastic Leukemias 11.2 Chronic Leukemias & Myeloproliferative Neoplasms 11.3 Multiple Myeloma & Plasma Cell Dyscrasias 11.4 Non-Malignant Hematologic Disorders: ITP, Aplastic Anemia, Sickle Cell Disease & TTP
12 Chapter 12: Lymphomas & Stem Cell Transplantation
12.1 Classical Hodgkin Lymphoma: Staging, Frontline Regimens & Relapsed/Refractory Strategies 12.2 Non-Hodgkin Lymphomas: Aggressive, Indolent, Mantle Cell & T-Cell Subtypes 12.3 Hematopoietic Stem Cell Transplantation, Complications & Graft-versus-Host Disease
13 Chapter 13: Supportive Care & Toxicity Management
13.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Prophylaxis & Rescue 13.2 Myelosuppression, Febrile Neutropenia & Growth Factor Stewardship 13.3 Oncologic Emergencies: TLS, Hypercalcemia, Spinal Cord Compression & SVCS 13.4 Chemotherapy Extravasation, Organ Protectants & Antidotes
14 Chapter 14: Hazardous Drug Handling & Compounding Safety
14.1 USP <800> & NIOSH Hazardous Drug Standards 14.2 Engineering Controls, Personal Protective Equipment & Closed System Transfer Devices 14.3 Safe Handling, Surface Decontamination & Accidental Spill Response
15 Chapter 15: Chemotherapy Safety, Dosing & Order Verification
15.1 Regimen Standardization, Dose Calculation Formulas & Organ Adjustments 15.2 Independent Double-Check, Verification Checkpoints & Toxicity Gating 15.3 Oral Chemotherapy Management, Adherence & Specialty Pharmacy Coordination
16 Chapter 16: Clinical Trials, Biostatistics & Evidence Evaluation
16.1 Oncology Clinical Trial Designs, Endpoints & Statistical Power 16.2 Biostatistical Concepts: Hazard Ratios, Survival Analysis & Precision Metrics 16.3 Evidence Synthesis, Guideline Hierarchy & Critical Literature Appraisal
17 Chapter 17: Health Systems, Regulatory Compliance & Patient Education
17.1 Oncology Formulary Management, Biosimilars & Value Frameworks 17.2 Regulatory Mandates, REMS Programs & Investigational Drug Services 17.3 Patient & Caregiver Counseling, Survivorship Care & Palliative Ethics 17.4 Complementary, Alternative & Integrative Therapies in Oncology
6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
Key Takeaways Explain This Topic AI
PARP inhibitors (olaparib, niraparib, rucaparib, talazoparib) exploit synthetic lethality in homologous recombination-deficient (HRD / BRCA1/2-mutated) malignancies by trapping PARP1/2 on single-strand DNA breaks, inducing replication fork collapse into catastrophic double-strand breaks.
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) arrest the cell cycle at the G1/S restriction point in HR+/HER2- breast cancer; clinical differences dictate selection: ribociclib requires ECG QTc and LFT monitoring, palbociclib features non-cumulative neutropenia on a 21/7 schedule, and continuous abemaciclib causes early-onset diarrhea requiring immediate loperamide protocols.
Venetoclax, a BH3-mimetic BCL-2 inhibitor, requires a strict 5-week dose ramp-up (20 to 400 mg daily in CLL) with vigorous hydration, uric acid lowering, and close electrolyte monitoring to prevent fatal Tumor Lysis Syndrome (TLS), alongside 50–75% dose reductions when co-administered with CYP3A4 inhibitors.
PI3K/AKT pathway inhibitors (alpelisib, capivasertib) require intensive metabolic and dermatologic surveillance; alpelisib targets PIK3CA-mutant breast cancer but frequently induces severe on-target hyperglycemia and rash, mandating baseline HbA1c screening, antidiabetic therapy (metformin), and proactive antihistamines.
The mTOR inhibitor everolimus produces unique class toxicities including non-infectious pneumonitis, metabolic dysregulation, and aphthous stomatitis, the latter of which is effectively prevented using the SWISH trial protocol of prophylactic alcohol-free dexamethasone oral solution.
Last updated: August 2026
6.3 Pathway-Specific Inhibitors: PARP, CDK4/6, BCL-2 & PI3K/AKT/mTOR Pathways
Beyond cell-surface receptor tyrosine kinases, precision oncology increasingly exploits intracellular enzymatic complexes governing DNA damage repair (DDR) , cell cycle checkpoints , mitochondrial apoptosis , and nutrient-sensing metabolic cascades . Targeting these downstream signaling nodes allows clinicians to achieve profound antitumor efficacy via mechanisms such as synthetic lethality , G1/S cell cycle arrest , and apoptotic priming .
Board-certified oncology pharmacists must maintain mastery over the dosing schedules, unique toxicity interception algorithms, pharmacokinetics, and drug-drug interactions of pathway-specific oral oncolytics.
1. PARP Inhibitors & Synthetic Lethality in HRD Malignancies
Poly(ADP-ribose) Polymerase 1 and 2 ( PARP1/2 ) are nuclear zinc-finger enzymes that detect DNA single-strand breaks (SSBs) and catalyze the synthesis of poly(ADP-ribose) (PAR) chains, recruiting base excision repair (BER) enzymes. PARP inhibitors ( olaparib, niraparib, rucaparib, talazoparib ) exert cytotoxicity through dual mechanisms:
Catalytic Inhibition: Competitive blockade of the NAD+ catalytic binding domain, preventing PARylation and repair of SSBs.
PARP Trapping: Trapping inactivated PARP1/2-DNA complexes directly onto damaged chromatin. When ongoing DNA replication forks collide with these immobilized PARP-DNA obstacles, the replication forks stall and collapse, generating lethal DNA double-strand breaks (DSBs) . +-----------------------------------------------------------------------------+
- | SYNTHETIC LETHALITY IN HRD MALIGNANCIES |
- | |
- | [NORMAL CELL (BRCA1/2 WILD-TYPE)] |
- | - PARP Inhibitor traps PARP -> DNA Single-Strand Breaks (SSBs) |
- | - Replication fork collapses into Double-Strand Breaks (DSBs) |
- | - Cell possesses INTACT HOMOLOGOUS RECOMBINATION (HR via BRCA1/2, PALB2, |
- | RAD51) -> Error-Free DSB Repair -> [CELL SURVIVES] |
- | |
- | [CANCER CELL WITH HRD (BRCA1/2 MUTATION / HRD-POSITIVE)] |
- | - PARP Inhibitor traps PARP -> Replication Fork Collapses into DSBs |
- | - Cell LACKS FUNCTIONAL HOMOLOGOUS RECOMBINATION REPAIR |
- | - Forced to use error-prone NHEJ -> Massive Genomic Aberrations, |
- | Chromosomal Translocations & Mitotic Catastrophe -> [CELL DIES] |
- +-----------------------------------------------------------------------------+
- PARP Trapping Potency & Clinical Pharmacotherapy
PARP Trapping Potency Hierarchy: Talazoparib (>>100x) > Niraparib > Olaparib = Rucaparib . High trapping potency correlates with lower required therapeutic dosages (talazoparib dose is 1 mg daily vs. olaparib 300 mg BID) and pronounced myelosuppression.
Secondary Myelodysplastic Syndrome / Acute Myeloid Leukemia (MDS/AML): Rare but potentially fatal class-effect toxicity occurring in 1–2% of patients treated with long-term PARP inhibitors (median onset 2–3 years post-initiation). Requires baseline CBC and monthly hematologic surveillance; persistent cytopenias mandate bone marrow biopsy and cytogenetic testing.
Transporter-Mediated Benign Serum Creatinine Elevations: Rucaparib and olaparib inhibit renal tubular transporters MATE1, MATE2-K, and OCT2 , reducing the tubular secretion of creatinine without altering true glomerular filtration rate (GFR). This manifests as a 10–25% asymptomatic rise in serum creatinine that stabilizes within weeks and resolves upon drug cessation. Pharmacists must verify normal cystatin C-based GFR or 24-hour urine creatinine clearance before unnecessarily discontinuing therapy.
Master PARP Inhibitor Comparison
Agent FDA-Approved Indications Standard Dosing & Schedule Dosing Adjustments & Key Practice Pearls
Olaparib - Ovarian cancer (adjuvant, maintenance); - Breast cancer (g BRCA + HER2- negative); - Pancreatic cancer (g BRCA + maintenance); - Prostate cancer (mCRPC with HRR mutations) 300 mg PO BID (two 150 mg tablets BID) Reduce to 200 mg BID for moderate renal impairment (CrCl 31–50 mL/min). CYP3A4 substrate (reduce dose with strong/moderate inhibitors). Take with or without food.
Niraparib - Advanced ovarian cancer (first-line and recurrent maintenance) Individualized Baseline Dosing: ; - Baseline weight < 77 kg OR Platelets < 150,000/mcL : 200 mg PO daily ; - Baseline weight >= 77 kg AND Platelets >= 150,000/mcL : 300 mg PO daily Individualized dosing based on baseline weight/platelets reduces Grade >=3 thrombocytopenia from 34% to 13% without loss of efficacy. Take at bedtime to minimize nausea.
Rucaparib - Recurrent ovarian cancer maintenance 600 mg PO BID Inhibits CYP1A2, CYP2C9, CYP3A4, and MATE1/OCT2. Significant benign serum creatinine elevation (in >50% of patients). ALT/AST elevations (transient, self-limiting).
Talazoparib - g BRCA + HER2- locally advanced/metastatic breast cancer; - mCRPC ( HRR -mutated) (+ Enzalutamide) 1 mg PO daily (0.75 mg daily when combined with enzalutamide) Highest PARP trapping potency. Severe myelosuppression (anemia in 50%, requiring transfusions). Reduce dose in moderate (0.5 mg) and severe (0.25 mg) renal impairment. P-gp substrate.
2. Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors in Breast Cancer
In Hormone Receptor-positive (HR+), Human Epidermal Growth Factor Receptor 2-negative (HER2-) breast cancer, oncogenic signaling (estrogen receptor, PI3K/AKT) upregulates Cyclin D1 , which binds and activates CDK4 and CDK6 . The activated CDK4/6 complex mono-phosphorylates the retinoblastoma tumor suppressor protein ( pRb ), initiating its hyperphosphorylation and releasing E2F transcription factors to drive cell cycle progression through the G1/S restriction point. +-----------------------------------------------------------------------------+
- | CDK4/6 INHIBITOR MECHANISM & PHARMACOLOGY |
- | |
- | Estrogen / Mitogenic Signals ---> Upregulate Cyclin D1 |
- | | |
- | v |
- | [CYCLIN D1 + CDK4 / CDK6 COMPLEX] <========== [CDK4/6 INHIBITORS] |
- | | - Palbociclib |
- | | (Hyperphosphorylates) - Ribociclib |
- | v - Abemaciclib |
- | [RETINOBLASTOMA PROTEIN (pRb)] |
- | | |
- | v (Releases) |
- | [E2F TRANSCRIPTION FACTORS] ===> [G1-to-S PHASE CELL CYCLE ARREST] |
- +-----------------------------------------------------------------------------+
- Landmark Clinical Trials & OS Benefits
Ribociclib (MONALEESA Trials): MONALEESA-2 (postmenopausal frontline + letrozole), MONALEESA-3 (postmenopausal frontline/second-line + fulvestrant), and MONALEESA-7 (pre/perimenopausal + endocrine + OFS) consistently demonstrated statistically significant overall survival (OS) improvements (median OS benefit >12 months; HRs 0.72–0.76) , establishing ribociclib as a preferred frontline CDK4/6 inhibitor.
Palbociclib (PALOMA Trials): PALOMA-2 and PALOMA-3 demonstrated substantial improvements in progression-free survival (PFS) when combined with endocrine therapy, though statistically significant OS superiority was not reached in the intent-to-treat populations.
Abemaciclib (monarchE & MONARCH Trials): In the adjuvant setting ( monarchE Trial ), abemaciclib (150 mg BID for 2 years) added to adjuvant endocrine therapy demonstrated a statistically significant improvement in Invasive Disease-Free Survival (IDFS: 5-year IDFS 83.6% vs. 76.0%; HR 0.68, p < 0.0001) in high-risk early breast cancer (>=4 positive lymph nodes, or 1–3 nodes with tumor size >=5 cm or Grade 3). In advanced disease (MONARCH-2/3), abemaciclib improved both PFS and OS.
Comparative CDK4/6 Inhibitor Matrix
- Parameter Palbociclib Ribociclib Abemaciclib
- Selectivity Potent CDK4 = CDK6 Potent CDK4 > CDK6 Potent CDK4 >> CDK6 (also inhibits CDK1, CDK2, CDK9)
Standard Dosing 125 mg PO daily for 21 days on / 7 days off (28-day cycle) 600 mg PO daily for 21 days on / 7 days off (28-day cycle) 150 mg PO BID (+ Endocrine/Adjuvant) or 200 mg PO BID (Monotherapy) CONTINUOUSLY
Food Effect Capsule: Take with food.; Tablet: With or without food. With or without food. With or without food.
Primary Toxicity Neutropenia (70–80%, Grade 3/4 in 60%) ; non-febrile, rapidly reversible Neutropenia, QTc Prolongation, Hepatotoxicity (transaminitis) Severe Diarrhea (80–85%, Grade 3 in 10–15%) , Venous Thromboembolism (VTE in 5%), Fatigue
Mandatory Monitoring CBC at baseline, Day 14 of first 2 cycles, then Day 1 of each cycle. - 12-lead ECG: Baseline, Day 14 of Cycle 1, and Day 1 of Cycle 2.; - LFTs: Baseline, every 2 weeks for first 2 cycles, then Day 1 of cycles 3–6. - Diarrhea intervention at first loose stool. ; - CBC and LFTs every 2 weeks for first 2 months.; - Monitor for signs of deep vein thrombosis/PE.
Creatinine Effect None None Inhibits OCT2/MATE1 , causing benign 0.2–0.4 mg/dL SCr rise without altering true GFR. +-----------------------------------------------------------------------------+
- | PHARMACIST-LED TOXICITY MANAGEMENT PROTOCOLS |
- | |
- | [ABEMACICLIB DIARRHEA MANAGEMENT ALGORITHM] |
- | - Median onset: Day 6 to 8 of Cycle 1 |
- | - Patient Education: Prescribe LOPERAMIDE at the start of therapy. |
- | - At first loose stool: Take 4 mg loperamide immediately, then 2 mg every |
- | 2 hours until diarrhea-free for 12 hours. Increase oral fluids. |
- | - If Grade 2 diarrhea persists >24h or any Grade 3 diarrhea: HOLD |
- | abemaciclib until <=Grade 1, then RESUME at next lower dose (100 mg BID)|
- | |
- | [RIBOCICLIB QTc SURVEILLANCE ALGORITHM] |
- | - If baseline QTcF > 450 ms: DO NOT INITIATE. |
- | - If QTcF > 480 ms during therapy: HOLD ribociclib. Correct electrolytes |
- | (K+ >= 4.0 mEq/L, Mg2+ >= 2.0 mg/dL). Resume at next lower dose level |
- | (400 mg daily) once QTcF < 481 ms. |
- | - If QTcF > 500 ms or change from baseline > 60 ms: HOLD until < 481 ms, |
- | then resume at 400 mg daily. Discontinue if QTcF > 500 ms recurs. |
- +-----------------------------------------------------------------------------+
- 3. BCL-2 Antagonism & Apoptosis Restoration: Venetoclax
B-Cell Lymphoma 2 ( BCL-2 ) is an anti-apoptotic outer mitochondrial membrane protein overexpressed in Chronic Lymphocytic Leukemia (CLL) and Acute Myeloid Leukemia (AML) . BCL-2 binds and sequesters pro-apoptotic BH3-only proteins (BIM, PUMA, BAX), preventing mitochondrial outer membrane permeabilization (MOMP) and rendering malignant cells resistant to programmed cell death.
Venetoclax is a first-in-class, orally bioavailable, highly selective BH3-mimetic . By binding with high affinity to the hydrophobic groove of BCL-2, venetoclax directly displaces pro-apoptotic BIM and BAX, triggering rapid BAX/BAK oligomerization, cytochrome c release into the cytosol, apoptosome assembly, and rapid apoptotic cell death. +-----------------------------------------------------------------------------+
- | VENETOCLAX 5-WEEK RAMP-UP SCHEDULE IN CLL |
- | |
- | WEEK 1: 20 mg PO Daily (Prevents hyper-acute massive blastolysis) |
- | | |
- | v |
- | WEEK 2: 50 mg PO Daily |
- | | |
- | v |
- | WEEK 3: 100 mg PO Daily |
- | | |
- | v |
- | WEEK 4: 200 mg PO Daily |
- | | |
- | v |
- | WEEK 5+: 400 mg PO Daily (Target Therapeutic Maintenance Dose) |
- +-----------------------------------------------------------------------------+
- CLL Tumor Lysis Syndrome (TLS) Risk Stratification & Prophylaxis
TLS Risk Category Defining Clinical Criteria Required Hydration & Prophylaxis Hospitalization & Lab Monitoring Mandates
Low Risk All lymph nodes < 5 cm AND ALC < 25,000/mcL Oral hydration (1.5–2 L/day) + Allopurinol (300 mg daily starting 2–3 days prior). Outpatient monitoring: Baseline chemistry, pre-dose lab, and 6–8 hours post-dose for Week 1 (20 mg) and Week 2 (50 mg).
Medium Risk Any lymph node 5 cm to < 10 cm OR ALC >= 25,000/mcL Oral hydration (1.5–2 L/day) + IV hydration as needed + Allopurinol. Outpatient monitoring (consider inpatient for CrCl <80 mL/min): Pre-dose, 6–8 hr, and 24 hr post-dose for Week 1 and Week 2 ramp-up.
High Risk Any lymph node >= 10 cm OR (Any lymph node >= 5 cm AND ALC >= 25,000/mcL ) Oral hydration (1.5–2 L/day) + IV hydration (150–200 mL/hr starting 12h pre-dose) + Allopurinol (consider Rasburicase if baseline uric acid elevated). MANDATORY INPATIENT HOSPITALIZATION for first dose of Week 1 (20 mg) and Week 2 (50 mg). Intensive lab monitoring at 0, 6, 8, 12, and 24 hours post-dose.
Critical Venetoclax Cytochrome P450 3A4 Interactions
Venetoclax is cleared exclusively via CYP3A4. Co-administration with CYP3A4 modulators alters systemic exposure dramatically:
Strong CYP3A4 Inhibitors (Ketoconazole, Posaconazole, Voriconazole, Clarithromycin): Increase venetoclax AUC by 5- to 8-fold , creating lethal TLS risk during ramp-up. Ramp-up phase: Concomitant use is contraindicated in CLL . Steady-state maintenance phase (400 mg): Reduce venetoclax dose by at least 75% (to 100 mg daily ; or 70 mg daily in AML posaconazole co-therapy).
Moderate CYP3A4 Inhibitors (Fluconazole, Diltiazem, Ciprofloxacin, Erythromycin, Grapefruit juice): Reduce venetoclax dose by at least 50% (to 200 mg daily ).
Administration: Always administer venetoclax with a meal and water (food increases bioavailability by 3- to 5-fold).
4. PI3K, AKT & mTOR Pathway Inhibitors
The PI3K-AKT-mTOR signaling network regulates cellular metabolism, nutrient uptake, protein synthesis, and survival. Hyperactivation occurs across solid tumors via PIK3CA activating mutations, PTEN loss-of-function, and AKT1 mutations. +-----------------------------------------------------------------------------+
- | THE PI3K / AKT / mTOR INHIBITOR AXIS |
- | |
- | Upstream RTKs (EGFR, HER2, IGFR) / Ras Activation |
- | | |
- | v |
- | [PI3K CATALYTIC SUBUNIT (p110-alpha)] <====== [ALPELISIB (SOLAR-1)] |
- | | |
- | v |
- | [PIP2 ===> PIP3] (Opposed by PTEN Phosphatase) |
- | | |
- | v |
- | [AKT (PROTEIN KINASE B)] <=================== [CAPIVASERTIB] |
- | | |
- | v |
- | [mTOR COMPLEX 1 (mTORC1)] <================== [EVEROLIMUS / TEMSIROLIMUS] |
- | | |
- | v |
- | [PROTEIN TRANSLATION, GLYCOLYSIS, CELL GROWTH & ANABOLISM] |
- +-----------------------------------------------------------------------------+
- Pharmacotherapy Matrix: PI3K, AKT & mTOR Inhibitors
Agent Target Class Key Indications Signature Toxicities & Monitoring Parameters Evidence-Based Clinical Management
Alpelisib PI3K-alpha selective PIK3CA -mutated HR+/HER2- metastatic breast cancer (+ Fulvestrant) per SOLAR-1 Severe On-Target Hyperglycemia (65%, Grade 3/4 in 35%) , Severe Cutaneous Adverse Reactions (rash in 50%, Grade 3 in 20%), Diarrhea, Pneumonitis. - Baseline Fasting Plasma Glucose (FPG <140 mg/dL) and HbA1c (<6.5%).; - Proactive antidiabetic management ( Metformin first-line; add SGLT2i / pioglitazone if FPG >=160 mg/dL).; - Prophylactic oral antihistamines (cetirizine 10 mg daily) reduce Grade >=2 rash from 60% to 26%.
Capivasertib Pan-AKT (AKT1/2/3) HR+/HER2- mBC with PIK3CA , AKT1 , or PTEN alterations (+ Fulvestrant) per CAPItello-291 Dosing: 400 mg PO BID, 4 days on / 3 days off. Diarrhea (70%, Grade 3 in 9%), cutaneous rash, hyperglycemia (Grade 3 in 2%). Intermittent 4-on/3-off schedule allows recovery from metabolic and mucosal toxicities. Manage diarrhea with early loperamide.
Everolimus mTORC1 Inhibitor - HR+/HER2- mBC (+ Exemestane) per BOLERO-2; - Advanced RCC, pNET, TSC Aphthous Stomatitis (60–70%) , Non-Infectious Pneumonitis (15%), Hyperglycemia, Hypertriglyceridemia, Impaired Wound Healing, Immunosuppression. - SWISH Trial Protocol: Prophylactic alcohol-free Dexamethasone 0.5 mg/5 mL oral solution (10 mL swish and spit QID for 8 weeks) reduces Grade >=2 stomatitis from 33% to 2%.; - Monitor for non-infectious pneumonitis (cough, dyspnea; hold for Grade >=2).
Temsirolimus Intravenous mTORC1 Advanced Renal Cell Carcinoma (poor prognosis) Asthenia, maculopapular rash, stomatitis, hyperlipidemia, hypersensitivity reactions. Dose: 25 mg IV weekly. Premedicate with IV diphenhydramine 25–50 mg to prevent infusion hypersensitivity reactions.